You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》比亞迪股價續跌 入市搏反彈可留意比迪認購19367
港股周二早段時候曾跌至23600點,其後恆指倒升至全日最高23863點水平,下午接近三時跌勢突然轉急,重回23600點,尾市稍有起色,跌幅收窄,最終全日靠穩只下跌7點,收報23739點。 汽車股整體走勢下跌,近日吉利(0175)、長城(2333)、比亞迪(1211)公佈其上月及去年全年的銷售量,吉利較預期銷售量為少,長城及比亞迪銷售量勝預期,其中大行、券商看好比亞迪的勢頭,亦預料比亞迪可以藉著其長期建立的品牌效應延續強勁的銷售量,紛紛上調對於比亞迪的買入評級及目標價。一眾汽車股股價沒有因消息而受帶動,反而受沽壓所影響表現偏弱。周五吉利下跌3.6%,收報18.9港元;長城下跌4.2%,收報24.3港元;比亞迪續跌1.8%,收報241.2港元。比亞迪股價從高位317港元至現時水平大幅回落近24%,亦逐漸邁向其200天線水平;資金流方面,比亞迪相關認購證得到顯著資金支持,投資者或趁比亞迪股價回落入市搏股價反彈,如投資者看好比亞迪,可留意比迪認購19367,行使價300.2港元,22年3月到期,有效槓桿約8.6倍。 周二藥明系列升幅亮麗,藥明(2269)升6%,收報87.65港元,為升幅最多的恆指成分股;藥明康德(2359)亦上升5.5%,收報127.5港元。由於新冠變種病毒仍然於全球肆虐,疫苗需求大增,最新藥明管理層表示有信心今年的營業額及利潤會進一步上升,亦再次明確被美國制裁的風險較低,藥明系股價得以受帶動。近日藥明股價持續波動,自去年年底疑被納入投資黑名單上股價曾挫至80港元以下水平,隨著藥明獲確認不會被納入黑名單上,事情得以明朗化;其後藥明亦先後多次回購其股份,股價上落波幅甚大。根據瑞銀周二記錄,投資者多以牛熊證作短線部署, 如投資者看好藥明,可留意藥明牛證68746,收回價75港元,行使價73.5港元,22年8月到期,有效槓桿約5.6倍。如投資者看淡藥明,可留意藥明熊證60751,收回價100港元,行使價101.5港元,22年7月到期,有效槓桿約6倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站:http://www.ubs.com/hkwarrants 窩證教學及巿焦點況短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 謝宛彤 瑞銀亞洲股票衍生產品銷售部 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account